Review



wdr5 inhibitor wdr5  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress wdr5 inhibitor wdr5
    (A–D) Wild-type (WT) T cells were labeled with CFSE and activated in the presence of MM-401, <t>WDR5-IN-4,</t> or DMSO. After 4 days, cells were analyzed by flow cytometry to assess the effects of MM-401 (A) and <t>WDR5-IN-4</t> (B) on cell division (CFSE dilution), and by RT-PCR to determine the effects of these inhibitors on Sell (C) and Tcf7 (D) transcription. Data are representative of two independent experiments. (E, F) Naïve CD8⁺ T cells were isolated from WT mice and activated in vitro for 4 days to generate activated T cells. Naïve and activated T cells were compared for Tcf7 expression by RT-PCR (E) and for H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (F). Data are representative of two independent experiments. (G, H) Mll1KO and WT T cells were activated in vitro and analyzed after 4 days for Tcf7 transcription by RT-PCR (G) and H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (H). Data are representative of three independent experiments. (I, J) Thymocytes and B cells were isolated from WT mice and compared for Tcf7 transcription by RT-PCR (I) and H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (J). Data are representative of two independent experiments.
    Wdr5 Inhibitor Wdr5, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/wdr5+in+4/WDR5-IN-4/bio_rxiv__64898__2026__04__03__715913-285-24-27
    Average 94 stars, based on 4 article reviews
    wdr5 inhibitor wdr5 - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "The MLL1–MENIN complex preserves CD8 T cell memory through a TOX–BTLA-TCF1 axis"

    Article Title: The MLL1–MENIN complex preserves CD8 T cell memory through a TOX–BTLA-TCF1 axis

    Journal: bioRxiv

    doi: 10.64898/2026.04.03.715913

    (A–D) Wild-type (WT) T cells were labeled with CFSE and activated in the presence of MM-401, WDR5-IN-4, or DMSO. After 4 days, cells were analyzed by flow cytometry to assess the effects of MM-401 (A) and WDR5-IN-4 (B) on cell division (CFSE dilution), and by RT-PCR to determine the effects of these inhibitors on Sell (C) and Tcf7 (D) transcription. Data are representative of two independent experiments. (E, F) Naïve CD8⁺ T cells were isolated from WT mice and activated in vitro for 4 days to generate activated T cells. Naïve and activated T cells were compared for Tcf7 expression by RT-PCR (E) and for H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (F). Data are representative of two independent experiments. (G, H) Mll1KO and WT T cells were activated in vitro and analyzed after 4 days for Tcf7 transcription by RT-PCR (G) and H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (H). Data are representative of three independent experiments. (I, J) Thymocytes and B cells were isolated from WT mice and compared for Tcf7 transcription by RT-PCR (I) and H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (J). Data are representative of two independent experiments.
    Figure Legend Snippet: (A–D) Wild-type (WT) T cells were labeled with CFSE and activated in the presence of MM-401, WDR5-IN-4, or DMSO. After 4 days, cells were analyzed by flow cytometry to assess the effects of MM-401 (A) and WDR5-IN-4 (B) on cell division (CFSE dilution), and by RT-PCR to determine the effects of these inhibitors on Sell (C) and Tcf7 (D) transcription. Data are representative of two independent experiments. (E, F) Naïve CD8⁺ T cells were isolated from WT mice and activated in vitro for 4 days to generate activated T cells. Naïve and activated T cells were compared for Tcf7 expression by RT-PCR (E) and for H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (F). Data are representative of two independent experiments. (G, H) Mll1KO and WT T cells were activated in vitro and analyzed after 4 days for Tcf7 transcription by RT-PCR (G) and H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (H). Data are representative of three independent experiments. (I, J) Thymocytes and B cells were isolated from WT mice and compared for Tcf7 transcription by RT-PCR (I) and H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (J). Data are representative of two independent experiments.

    Techniques Used: Labeling, Flow Cytometry, Reverse Transcription Polymerase Chain Reaction, Isolation, In Vitro, Expressing

    (A) Wild-type (WT) T cells were activated in the presence of WDR5-IN-4, MM-401, or DMSO. After 4 days, cells were collected and analyzed for Tox expression by RT-PCR. Data are representative of two independent experiments. (B, E) T cells from Mll1KO mice and their WT littermates were activated in vitro. After 4 days, cells were collected and analyzed for H3K4me3 (B) and H4K16ac (E) enrichment at the Tox locus by ChIP-PCR. Data are representative of three independent experiments. (C, D, F) Thymocytes and B cells were isolated from WT mice and compared for Tox expression by RT-PCR (C), and for H3K4me3 (D) and H4K16ac (F) enrichment at the Tox locus by ChIP-PCR. Data are representative of two independent experiments. (G, H) T cells from Mll1KO mice and their WT littermates were activated in the presence of MI-3454 or DMSO. After 4 days, cells were collected and analyzed for Tox (G) and Btla (H) expression by RT-PCR. Data are representative of two independent experiments.
    Figure Legend Snippet: (A) Wild-type (WT) T cells were activated in the presence of WDR5-IN-4, MM-401, or DMSO. After 4 days, cells were collected and analyzed for Tox expression by RT-PCR. Data are representative of two independent experiments. (B, E) T cells from Mll1KO mice and their WT littermates were activated in vitro. After 4 days, cells were collected and analyzed for H3K4me3 (B) and H4K16ac (E) enrichment at the Tox locus by ChIP-PCR. Data are representative of three independent experiments. (C, D, F) Thymocytes and B cells were isolated from WT mice and compared for Tox expression by RT-PCR (C), and for H3K4me3 (D) and H4K16ac (F) enrichment at the Tox locus by ChIP-PCR. Data are representative of two independent experiments. (G, H) T cells from Mll1KO mice and their WT littermates were activated in the presence of MI-3454 or DMSO. After 4 days, cells were collected and analyzed for Tox (G) and Btla (H) expression by RT-PCR. Data are representative of two independent experiments.

    Techniques Used: Expressing, Reverse Transcription Polymerase Chain Reaction, In Vitro, Isolation

    Related Articles

    Transduction:

    Article Title: SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma
    Article Snippet: Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.. The following compounds were used in this study: SGF29-IN-1 (cat# HY-158009, MedChemExpress), GSK4027 (cat# SML2018, Sigma Aldrich), CPTH2 (cat# J65939LB0, ThermoFisher), garcinol (cat# 14076, Active Motif), USP22si-02 (cat# SML3875, Sigma Aldrich), WDR5-IN-4 (WIN site inhibitor, cat# HY-111753, MedChemExpress), WDR5-IN-6 (WBM site inhibitor, cat# T77495, TargetMol), OICR9429 (cat# T6916, TargetMol), WM586 (WDR5/Myc inhibitor, cat# HY-153728, MedChemExpress), YM-53601 (cat# HY-100313A, MedChemExpress), NB-598 (cat# HY-16343, MedChemExpress), terbinafine (cat# T3677, TCI Chemicals), Atorvastatin (cat# SML3030, Sigma Aldrich), and Pitavastatin (cat# AMBH2D6EF677, Ambeed)

    Knockdown:

    Article Title: SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma
    Article Snippet: Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.. The following compounds were used in this study: SGF29-IN-1 (cat# HY-158009, MedChemExpress), GSK4027 (cat# SML2018, Sigma Aldrich), CPTH2 (cat# J65939LB0, ThermoFisher), garcinol (cat# 14076, Active Motif), USP22si-02 (cat# SML3875, Sigma Aldrich), WDR5-IN-4 (WIN site inhibitor, cat# HY-111753, MedChemExpress), WDR5-IN-6 (WBM site inhibitor, cat# T77495, TargetMol), OICR9429 (cat# T6916, TargetMol), WM586 (WDR5/Myc inhibitor, cat# HY-153728, MedChemExpress), YM-53601 (cat# HY-100313A, MedChemExpress), NB-598 (cat# HY-16343, MedChemExpress), terbinafine (cat# T3677, TCI Chemicals), Atorvastatin (cat# SML3030, Sigma Aldrich), and Pitavastatin (cat# AMBH2D6EF677, Ambeed)

    Control:

    Article Title: SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma
    Article Snippet: Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.. The following compounds were used in this study: SGF29-IN-1 (cat# HY-158009, MedChemExpress), GSK4027 (cat# SML2018, Sigma Aldrich), CPTH2 (cat# J65939LB0, ThermoFisher), garcinol (cat# 14076, Active Motif), USP22si-02 (cat# SML3875, Sigma Aldrich), WDR5-IN-4 (WIN site inhibitor, cat# HY-111753, MedChemExpress), WDR5-IN-6 (WBM site inhibitor, cat# T77495, TargetMol), OICR9429 (cat# T6916, TargetMol), WM586 (WDR5/Myc inhibitor, cat# HY-153728, MedChemExpress), YM-53601 (cat# HY-100313A, MedChemExpress), NB-598 (cat# HY-16343, MedChemExpress), terbinafine (cat# T3677, TCI Chemicals), Atorvastatin (cat# SML3030, Sigma Aldrich), and Pitavastatin (cat# AMBH2D6EF677, Ambeed)

    shRNA:

    Article Title: SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma
    Article Snippet: Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.. The following compounds were used in this study: SGF29-IN-1 (cat# HY-158009, MedChemExpress), GSK4027 (cat# SML2018, Sigma Aldrich), CPTH2 (cat# J65939LB0, ThermoFisher), garcinol (cat# 14076, Active Motif), USP22si-02 (cat# SML3875, Sigma Aldrich), WDR5-IN-4 (WIN site inhibitor, cat# HY-111753, MedChemExpress), WDR5-IN-6 (WBM site inhibitor, cat# T77495, TargetMol), OICR9429 (cat# T6916, TargetMol), WM586 (WDR5/Myc inhibitor, cat# HY-153728, MedChemExpress), YM-53601 (cat# HY-100313A, MedChemExpress), NB-598 (cat# HY-16343, MedChemExpress), terbinafine (cat# T3677, TCI Chemicals), Atorvastatin (cat# SML3030, Sigma Aldrich), and Pitavastatin (cat# AMBH2D6EF677, Ambeed)

    Expressing:

    Article Title: SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma
    Article Snippet: Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.. The following compounds were used in this study: SGF29-IN-1 (cat# HY-158009, MedChemExpress), GSK4027 (cat# SML2018, Sigma Aldrich), CPTH2 (cat# J65939LB0, ThermoFisher), garcinol (cat# 14076, Active Motif), USP22si-02 (cat# SML3875, Sigma Aldrich), WDR5-IN-4 (WIN site inhibitor, cat# HY-111753, MedChemExpress), WDR5-IN-6 (WBM site inhibitor, cat# T77495, TargetMol), OICR9429 (cat# T6916, TargetMol), WM586 (WDR5/Myc inhibitor, cat# HY-153728, MedChemExpress), YM-53601 (cat# HY-100313A, MedChemExpress), NB-598 (cat# HY-16343, MedChemExpress), terbinafine (cat# T3677, TCI Chemicals), Atorvastatin (cat# SML3030, Sigma Aldrich), and Pitavastatin (cat# AMBH2D6EF677, Ambeed)

    Plasmid Preparation:

    Article Title: SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma
    Article Snippet: Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.. The following compounds were used in this study: SGF29-IN-1 (cat# HY-158009, MedChemExpress), GSK4027 (cat# SML2018, Sigma Aldrich), CPTH2 (cat# J65939LB0, ThermoFisher), garcinol (cat# 14076, Active Motif), USP22si-02 (cat# SML3875, Sigma Aldrich), WDR5-IN-4 (WIN site inhibitor, cat# HY-111753, MedChemExpress), WDR5-IN-6 (WBM site inhibitor, cat# T77495, TargetMol), OICR9429 (cat# T6916, TargetMol), WM586 (WDR5/Myc inhibitor, cat# HY-153728, MedChemExpress), YM-53601 (cat# HY-100313A, MedChemExpress), NB-598 (cat# HY-16343, MedChemExpress), terbinafine (cat# T3677, TCI Chemicals), Atorvastatin (cat# SML3030, Sigma Aldrich), and Pitavastatin (cat# AMBH2D6EF677, Ambeed)

    Activity Assay:

    Article Title: SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma
    Article Snippet: Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.. The following compounds were used in this study: SGF29-IN-1 (cat# HY-158009, MedChemExpress), GSK4027 (cat# SML2018, Sigma Aldrich), CPTH2 (cat# J65939LB0, ThermoFisher), garcinol (cat# 14076, Active Motif), USP22si-02 (cat# SML3875, Sigma Aldrich), WDR5-IN-4 (WIN site inhibitor, cat# HY-111753, MedChemExpress), WDR5-IN-6 (WBM site inhibitor, cat# T77495, TargetMol), OICR9429 (cat# T6916, TargetMol), WM586 (WDR5/Myc inhibitor, cat# HY-153728, MedChemExpress), YM-53601 (cat# HY-100313A, MedChemExpress), NB-598 (cat# HY-16343, MedChemExpress), terbinafine (cat# T3677, TCI Chemicals), Atorvastatin (cat# SML3030, Sigma Aldrich), and Pitavastatin (cat# AMBH2D6EF677, Ambeed)

    Inhibition:

    Article Title: SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma
    Article Snippet: Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.. The following compounds were used in this study: SGF29-IN-1 (cat# HY-158009, MedChemExpress), GSK4027 (cat# SML2018, Sigma Aldrich), CPTH2 (cat# J65939LB0, ThermoFisher), garcinol (cat# 14076, Active Motif), USP22si-02 (cat# SML3875, Sigma Aldrich), WDR5-IN-4 (WIN site inhibitor, cat# HY-111753, MedChemExpress), WDR5-IN-6 (WBM site inhibitor, cat# T77495, TargetMol), OICR9429 (cat# T6916, TargetMol), WM586 (WDR5/Myc inhibitor, cat# HY-153728, MedChemExpress), YM-53601 (cat# HY-100313A, MedChemExpress), NB-598 (cat# HY-16343, MedChemExpress), terbinafine (cat# T3677, TCI Chemicals), Atorvastatin (cat# SML3030, Sigma Aldrich), and Pitavastatin (cat# AMBH2D6EF677, Ambeed)

    Ubiquitin Proteomics:

    Article Title: SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma
    Article Snippet: Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.. The following compounds were used in this study: SGF29-IN-1 (cat# HY-158009, MedChemExpress), GSK4027 (cat# SML2018, Sigma Aldrich), CPTH2 (cat# J65939LB0, ThermoFisher), garcinol (cat# 14076, Active Motif), USP22si-02 (cat# SML3875, Sigma Aldrich), WDR5-IN-4 (WIN site inhibitor, cat# HY-111753, MedChemExpress), WDR5-IN-6 (WBM site inhibitor, cat# T77495, TargetMol), OICR9429 (cat# T6916, TargetMol), WM586 (WDR5/Myc inhibitor, cat# HY-153728, MedChemExpress), YM-53601 (cat# HY-100313A, MedChemExpress), NB-598 (cat# HY-16343, MedChemExpress), terbinafine (cat# T3677, TCI Chemicals), Atorvastatin (cat# SML3030, Sigma Aldrich), and Pitavastatin (cat# AMBH2D6EF677, Ambeed)

    Methylation:

    Article Title: SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma
    Article Snippet: Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.. The following compounds were used in this study: SGF29-IN-1 (cat# HY-158009, MedChemExpress), GSK4027 (cat# SML2018, Sigma Aldrich), CPTH2 (cat# J65939LB0, ThermoFisher), garcinol (cat# 14076, Active Motif), USP22si-02 (cat# SML3875, Sigma Aldrich), WDR5-IN-4 (WIN site inhibitor, cat# HY-111753, MedChemExpress), WDR5-IN-6 (WBM site inhibitor, cat# T77495, TargetMol), OICR9429 (cat# T6916, TargetMol), WM586 (WDR5/Myc inhibitor, cat# HY-153728, MedChemExpress), YM-53601 (cat# HY-100313A, MedChemExpress), NB-598 (cat# HY-16343, MedChemExpress), terbinafine (cat# T3677, TCI Chemicals), Atorvastatin (cat# SML3030, Sigma Aldrich), and Pitavastatin (cat# AMBH2D6EF677, Ambeed)

    Mutagenesis:

    Article Title: SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma
    Article Snippet: Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.. The following compounds were used in this study: SGF29-IN-1 (cat# HY-158009, MedChemExpress), GSK4027 (cat# SML2018, Sigma Aldrich), CPTH2 (cat# J65939LB0, ThermoFisher), garcinol (cat# 14076, Active Motif), USP22si-02 (cat# SML3875, Sigma Aldrich), WDR5-IN-4 (WIN site inhibitor, cat# HY-111753, MedChemExpress), WDR5-IN-6 (WBM site inhibitor, cat# T77495, TargetMol), OICR9429 (cat# T6916, TargetMol), WM586 (WDR5/Myc inhibitor, cat# HY-153728, MedChemExpress), YM-53601 (cat# HY-100313A, MedChemExpress), NB-598 (cat# HY-16343, MedChemExpress), terbinafine (cat# T3677, TCI Chemicals), Atorvastatin (cat# SML3030, Sigma Aldrich), and Pitavastatin (cat# AMBH2D6EF677, Ambeed)

    Transformation Assay:

    Article Title: SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma
    Article Snippet: Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.. The following compounds were used in this study: SGF29-IN-1 (cat# HY-158009, MedChemExpress), GSK4027 (cat# SML2018, Sigma Aldrich), CPTH2 (cat# J65939LB0, ThermoFisher), garcinol (cat# 14076, Active Motif), USP22si-02 (cat# SML3875, Sigma Aldrich), WDR5-IN-4 (WIN site inhibitor, cat# HY-111753, MedChemExpress), WDR5-IN-6 (WBM site inhibitor, cat# T77495, TargetMol), OICR9429 (cat# T6916, TargetMol), WM586 (WDR5/Myc inhibitor, cat# HY-153728, MedChemExpress), YM-53601 (cat# HY-100313A, MedChemExpress), NB-598 (cat# HY-16343, MedChemExpress), terbinafine (cat# T3677, TCI Chemicals), Atorvastatin (cat# SML3030, Sigma Aldrich), and Pitavastatin (cat# AMBH2D6EF677, Ambeed)

    Western Blot:

    Article Title: SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma
    Article Snippet: Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.. The following compounds were used in this study: SGF29-IN-1 (cat# HY-158009, MedChemExpress), GSK4027 (cat# SML2018, Sigma Aldrich), CPTH2 (cat# J65939LB0, ThermoFisher), garcinol (cat# 14076, Active Motif), USP22si-02 (cat# SML3875, Sigma Aldrich), WDR5-IN-4 (WIN site inhibitor, cat# HY-111753, MedChemExpress), WDR5-IN-6 (WBM site inhibitor, cat# T77495, TargetMol), OICR9429 (cat# T6916, TargetMol), WM586 (WDR5/Myc inhibitor, cat# HY-153728, MedChemExpress), YM-53601 (cat# HY-100313A, MedChemExpress), NB-598 (cat# HY-16343, MedChemExpress), terbinafine (cat# T3677, TCI Chemicals), Atorvastatin (cat# SML3030, Sigma Aldrich), and Pitavastatin (cat# AMBH2D6EF677, Ambeed)

    Quantitative Proteomics:

    Article Title: SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma
    Article Snippet: Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.Small molecule inhibitors targeting various SAGA/ATAC-associated proteins or cholesterol synthesis enzymes were re-suspended in DMSO.. The following compounds were used in this study: SGF29-IN-1 (cat# HY-158009, MedChemExpress), GSK4027 (cat# SML2018, Sigma Aldrich), CPTH2 (cat# J65939LB0, ThermoFisher), garcinol (cat# 14076, Active Motif), USP22si-02 (cat# SML3875, Sigma Aldrich), WDR5-IN-4 (WIN site inhibitor, cat# HY-111753, MedChemExpress), WDR5-IN-6 (WBM site inhibitor, cat# T77495, TargetMol), OICR9429 (cat# T6916, TargetMol), WM586 (WDR5/Myc inhibitor, cat# HY-153728, MedChemExpress), YM-53601 (cat# HY-100313A, MedChemExpress), NB-598 (cat# HY-16343, MedChemExpress), terbinafine (cat# T3677, TCI Chemicals), Atorvastatin (cat# SML3030, Sigma Aldrich), and Pitavastatin (cat# AMBH2D6EF677, Ambeed)



    Similar Products

    mv4 11 cells expressing hibit tagged wdr5 engineered  (ATCC)
    99
    ATCC mv4 11 cells expressing hibit tagged wdr5 engineered
    Mv4 11 Cells Expressing Hibit Tagged Wdr5 Engineered, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/wdr5+in+4/MV-4-11/pmc11585590__41467_2024_54500_MOESM2_ESM-37-13-24
    Average 99 stars, based on 1 article reviews
    mv4 11 cells expressing hibit tagged wdr5 engineered - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    wdr5 inhibitor wdr5  (MedChemExpress)
    94
    MedChemExpress wdr5 inhibitor wdr5
    (A–D) Wild-type (WT) T cells were labeled with CFSE and activated in the presence of MM-401, <t>WDR5-IN-4,</t> or DMSO. After 4 days, cells were analyzed by flow cytometry to assess the effects of MM-401 (A) and <t>WDR5-IN-4</t> (B) on cell division (CFSE dilution), and by RT-PCR to determine the effects of these inhibitors on Sell (C) and Tcf7 (D) transcription. Data are representative of two independent experiments. (E, F) Naïve CD8⁺ T cells were isolated from WT mice and activated in vitro for 4 days to generate activated T cells. Naïve and activated T cells were compared for Tcf7 expression by RT-PCR (E) and for H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (F). Data are representative of two independent experiments. (G, H) Mll1KO and WT T cells were activated in vitro and analyzed after 4 days for Tcf7 transcription by RT-PCR (G) and H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (H). Data are representative of three independent experiments. (I, J) Thymocytes and B cells were isolated from WT mice and compared for Tcf7 transcription by RT-PCR (I) and H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (J). Data are representative of two independent experiments.
    Wdr5 Inhibitor Wdr5, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/wdr5+in+4/WDR5-IN-4/bio_rxiv__64898__2026__04__03__715913-285-24-27
    Average 94 stars, based on 1 article reviews
    wdr5 inhibitor wdr5 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    wdr5 in 4  (TargetMol)
    94
    TargetMol wdr5 in 4
    a, Growth curves of SU-DIPGXIII cells transduced with shRNAs to knockdown both KAT2A and KAT2B, showing significantly reduced growth compared to control shRNA-transduced cells. b, Number of live SU-DIPGXIII+Cas9 cells expressing a control plasmid (HA/flag-GFP) or sgRNAs to KO SAGA-associated acetyltransferase activity ( TADA2B sgRNAs), or de-ubiquitinase activity ( ENY2 sgRNA). c, Schematic illustrating inhibition of histone-modifying modules of SAGA/ATAC complexes using chemical probes to target SAGA/ATAC-dependent histone acetylation (GSK4027, CPTH2, garcinol), SAGA-dependent H2A/H2B de-ubiquitination (USP22si-02), or <t>WDR5-mediated</t> H3K4me3 methylation (OICR-9529, WM856, <t>WDR5-IN-4,</t> and WDR5-IN-6). d, Average normalized cell viability from CellTiter-Glo assays conducted seven days after starting treatment of H3K27M mutant cells (teal curves) or non-transformed, H3 wildtype, control cells (black curves) with increasing doses of the KAT2A/2B bromodomain-targeting acetyltransferase inhibitor, GSK4027. e, Immunoblots confirming that treatment of BT245 cells with GSK4027 reduced H3K9ac in a dose-dependent manner, but not total H3 or SGF29 protein abundance. f-h, Dose response curves showing inhibition of H3K27M mutant DMG cell viability, but no effect on control H3 wild-type cells (black curves) following seven days of treatment with the DUB inhibitor, USP22i-S02 ( f, yellow curves), the WDR5 WIN site inhibitor, WDR5-IN-4 ( g, blue curves), or the WDR5 WBM site inhibitor, WDR5-IN-6 ( h, blue curves). i-j Average number of live SU-DIPGXIIIP*+ZsG/luc cells ( i ), and average BT245 ( j ) cell viability (CellTiter-Glo) following treatment with combinations of GSK4027 and USP22si-02 to simultaneously target both SAGA/ATAC-dependent histone acetyltransferase activity and SAGA-dependent H2A/H2B de-ubiquitination. k-l, BLISS synergy plots showing a combined effect of GSK4027 and WDR5-IN-6 treatment in reducing SU-DIPGXIIIP*+ZsG/luc growth ( k, **p<1.74×10 -3 ), and a combined effect of GSK4027 and WDR5-IN-4 treatment in reducing BT245 cell growth ( l , ****p<2.5×10 -10 ).
    Wdr5 In 4, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/wdr5+in+4/WDR5-IN-4/bio_rxiv__64898__2026__01__22__701194-211-31-44
    Average 94 stars, based on 1 article reviews
    wdr5 in 4 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    sirna wdr5 #1 sirna pool (4 targets mixture)  (Thermo Fisher)
    90
    Thermo Fisher sirna wdr5 #1 sirna pool (4 targets mixture)
    a, Growth curves of SU-DIPGXIII cells transduced with shRNAs to knockdown both KAT2A and KAT2B, showing significantly reduced growth compared to control shRNA-transduced cells. b, Number of live SU-DIPGXIII+Cas9 cells expressing a control plasmid (HA/flag-GFP) or sgRNAs to KO SAGA-associated acetyltransferase activity ( TADA2B sgRNAs), or de-ubiquitinase activity ( ENY2 sgRNA). c, Schematic illustrating inhibition of histone-modifying modules of SAGA/ATAC complexes using chemical probes to target SAGA/ATAC-dependent histone acetylation (GSK4027, CPTH2, garcinol), SAGA-dependent H2A/H2B de-ubiquitination (USP22si-02), or <t>WDR5-mediated</t> H3K4me3 methylation (OICR-9529, WM856, <t>WDR5-IN-4,</t> and WDR5-IN-6). d, Average normalized cell viability from CellTiter-Glo assays conducted seven days after starting treatment of H3K27M mutant cells (teal curves) or non-transformed, H3 wildtype, control cells (black curves) with increasing doses of the KAT2A/2B bromodomain-targeting acetyltransferase inhibitor, GSK4027. e, Immunoblots confirming that treatment of BT245 cells with GSK4027 reduced H3K9ac in a dose-dependent manner, but not total H3 or SGF29 protein abundance. f-h, Dose response curves showing inhibition of H3K27M mutant DMG cell viability, but no effect on control H3 wild-type cells (black curves) following seven days of treatment with the DUB inhibitor, USP22i-S02 ( f, yellow curves), the WDR5 WIN site inhibitor, WDR5-IN-4 ( g, blue curves), or the WDR5 WBM site inhibitor, WDR5-IN-6 ( h, blue curves). i-j Average number of live SU-DIPGXIIIP*+ZsG/luc cells ( i ), and average BT245 ( j ) cell viability (CellTiter-Glo) following treatment with combinations of GSK4027 and USP22si-02 to simultaneously target both SAGA/ATAC-dependent histone acetyltransferase activity and SAGA-dependent H2A/H2B de-ubiquitination. k-l, BLISS synergy plots showing a combined effect of GSK4027 and WDR5-IN-6 treatment in reducing SU-DIPGXIIIP*+ZsG/luc growth ( k, **p<1.74×10 -3 ), and a combined effect of GSK4027 and WDR5-IN-4 treatment in reducing BT245 cell growth ( l , ****p<2.5×10 -10 ).
    Sirna Wdr5 #1 Sirna Pool (4 Targets Mixture), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/wdr5+in+4/human+wdr5+sirna+smart+pool/pmc11570632__41419_2024_7229_MOESM1_ESM-167-4-15
    Average 90 stars, based on 1 article reviews
    sirna wdr5 #1 sirna pool (4 targets mixture) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    wdr5 in 4  (MedChemExpress)
    94
    MedChemExpress wdr5 in 4
    a, Growth curves of SU-DIPGXIII cells transduced with shRNAs to knockdown both KAT2A and KAT2B, showing significantly reduced growth compared to control shRNA-transduced cells. b, Number of live SU-DIPGXIII+Cas9 cells expressing a control plasmid (HA/flag-GFP) or sgRNAs to KO SAGA-associated acetyltransferase activity ( TADA2B sgRNAs), or de-ubiquitinase activity ( ENY2 sgRNA). c, Schematic illustrating inhibition of histone-modifying modules of SAGA/ATAC complexes using chemical probes to target SAGA/ATAC-dependent histone acetylation (GSK4027, CPTH2, garcinol), SAGA-dependent H2A/H2B de-ubiquitination (USP22si-02), or <t>WDR5-mediated</t> H3K4me3 methylation (OICR-9529, WM856, <t>WDR5-IN-4,</t> and WDR5-IN-6). d, Average normalized cell viability from CellTiter-Glo assays conducted seven days after starting treatment of H3K27M mutant cells (teal curves) or non-transformed, H3 wildtype, control cells (black curves) with increasing doses of the KAT2A/2B bromodomain-targeting acetyltransferase inhibitor, GSK4027. e, Immunoblots confirming that treatment of BT245 cells with GSK4027 reduced H3K9ac in a dose-dependent manner, but not total H3 or SGF29 protein abundance. f-h, Dose response curves showing inhibition of H3K27M mutant DMG cell viability, but no effect on control H3 wild-type cells (black curves) following seven days of treatment with the DUB inhibitor, USP22i-S02 ( f, yellow curves), the WDR5 WIN site inhibitor, WDR5-IN-4 ( g, blue curves), or the WDR5 WBM site inhibitor, WDR5-IN-6 ( h, blue curves). i-j Average number of live SU-DIPGXIIIP*+ZsG/luc cells ( i ), and average BT245 ( j ) cell viability (CellTiter-Glo) following treatment with combinations of GSK4027 and USP22si-02 to simultaneously target both SAGA/ATAC-dependent histone acetyltransferase activity and SAGA-dependent H2A/H2B de-ubiquitination. k-l, BLISS synergy plots showing a combined effect of GSK4027 and WDR5-IN-6 treatment in reducing SU-DIPGXIIIP*+ZsG/luc growth ( k, **p<1.74×10 -3 ), and a combined effect of GSK4027 and WDR5-IN-4 treatment in reducing BT245 cell growth ( l , ****p<2.5×10 -10 ).
    Wdr5 In 4, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/wdr5+in+4/WDR5-IN-4/bio_rxiv__64898__2026__01__22__701194-211-31-37
    Average 94 stars, based on 1 article reviews
    wdr5 in 4 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    wdr5in 4  (MedChemExpress)
    94
    MedChemExpress wdr5in 4
    a, Growth curves of SU-DIPGXIII cells transduced with shRNAs to knockdown both KAT2A and KAT2B, showing significantly reduced growth compared to control shRNA-transduced cells. b, Number of live SU-DIPGXIII+Cas9 cells expressing a control plasmid (HA/flag-GFP) or sgRNAs to KO SAGA-associated acetyltransferase activity ( TADA2B sgRNAs), or de-ubiquitinase activity ( ENY2 sgRNA). c, Schematic illustrating inhibition of histone-modifying modules of SAGA/ATAC complexes using chemical probes to target SAGA/ATAC-dependent histone acetylation (GSK4027, CPTH2, garcinol), SAGA-dependent H2A/H2B de-ubiquitination (USP22si-02), or <t>WDR5-mediated</t> H3K4me3 methylation (OICR-9529, WM856, <t>WDR5-IN-4,</t> and WDR5-IN-6). d, Average normalized cell viability from CellTiter-Glo assays conducted seven days after starting treatment of H3K27M mutant cells (teal curves) or non-transformed, H3 wildtype, control cells (black curves) with increasing doses of the KAT2A/2B bromodomain-targeting acetyltransferase inhibitor, GSK4027. e, Immunoblots confirming that treatment of BT245 cells with GSK4027 reduced H3K9ac in a dose-dependent manner, but not total H3 or SGF29 protein abundance. f-h, Dose response curves showing inhibition of H3K27M mutant DMG cell viability, but no effect on control H3 wild-type cells (black curves) following seven days of treatment with the DUB inhibitor, USP22i-S02 ( f, yellow curves), the WDR5 WIN site inhibitor, WDR5-IN-4 ( g, blue curves), or the WDR5 WBM site inhibitor, WDR5-IN-6 ( h, blue curves). i-j Average number of live SU-DIPGXIIIP*+ZsG/luc cells ( i ), and average BT245 ( j ) cell viability (CellTiter-Glo) following treatment with combinations of GSK4027 and USP22si-02 to simultaneously target both SAGA/ATAC-dependent histone acetyltransferase activity and SAGA-dependent H2A/H2B de-ubiquitination. k-l, BLISS synergy plots showing a combined effect of GSK4027 and WDR5-IN-6 treatment in reducing SU-DIPGXIIIP*+ZsG/luc growth ( k, **p<1.74×10 -3 ), and a combined effect of GSK4027 and WDR5-IN-4 treatment in reducing BT245 cell growth ( l , ****p<2.5×10 -10 ).
    Wdr5in 4, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/wdr5+in+4/WDR5-IN-4/10__7554_slash_elife__94657__3-207-0-4
    Average 94 stars, based on 1 article reviews
    wdr5in 4 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    wdr5  (MedChemExpress)
    94
    MedChemExpress wdr5
    a, Growth curves of SU-DIPGXIII cells transduced with shRNAs to knockdown both KAT2A and KAT2B, showing significantly reduced growth compared to control shRNA-transduced cells. b, Number of live SU-DIPGXIII+Cas9 cells expressing a control plasmid (HA/flag-GFP) or sgRNAs to KO SAGA-associated acetyltransferase activity ( TADA2B sgRNAs), or de-ubiquitinase activity ( ENY2 sgRNA). c, Schematic illustrating inhibition of histone-modifying modules of SAGA/ATAC complexes using chemical probes to target SAGA/ATAC-dependent histone acetylation (GSK4027, CPTH2, garcinol), SAGA-dependent H2A/H2B de-ubiquitination (USP22si-02), or <t>WDR5-mediated</t> H3K4me3 methylation (OICR-9529, WM856, <t>WDR5-IN-4,</t> and WDR5-IN-6). d, Average normalized cell viability from CellTiter-Glo assays conducted seven days after starting treatment of H3K27M mutant cells (teal curves) or non-transformed, H3 wildtype, control cells (black curves) with increasing doses of the KAT2A/2B bromodomain-targeting acetyltransferase inhibitor, GSK4027. e, Immunoblots confirming that treatment of BT245 cells with GSK4027 reduced H3K9ac in a dose-dependent manner, but not total H3 or SGF29 protein abundance. f-h, Dose response curves showing inhibition of H3K27M mutant DMG cell viability, but no effect on control H3 wild-type cells (black curves) following seven days of treatment with the DUB inhibitor, USP22i-S02 ( f, yellow curves), the WDR5 WIN site inhibitor, WDR5-IN-4 ( g, blue curves), or the WDR5 WBM site inhibitor, WDR5-IN-6 ( h, blue curves). i-j Average number of live SU-DIPGXIIIP*+ZsG/luc cells ( i ), and average BT245 ( j ) cell viability (CellTiter-Glo) following treatment with combinations of GSK4027 and USP22si-02 to simultaneously target both SAGA/ATAC-dependent histone acetyltransferase activity and SAGA-dependent H2A/H2B de-ubiquitination. k-l, BLISS synergy plots showing a combined effect of GSK4027 and WDR5-IN-6 treatment in reducing SU-DIPGXIIIP*+ZsG/luc growth ( k, **p<1.74×10 -3 ), and a combined effect of GSK4027 and WDR5-IN-4 treatment in reducing BT245 cell growth ( l , ****p<2.5×10 -10 ).
    Wdr5, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/wdr5+in+4/WDR5-IN-4/pmc11554307-224-0-3
    Average 94 stars, based on 1 article reviews
    wdr5 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    hy 111753a  (MedChemExpress)
    94
    MedChemExpress hy 111753a
    a, Growth curves of SU-DIPGXIII cells transduced with shRNAs to knockdown both KAT2A and KAT2B, showing significantly reduced growth compared to control shRNA-transduced cells. b, Number of live SU-DIPGXIII+Cas9 cells expressing a control plasmid (HA/flag-GFP) or sgRNAs to KO SAGA-associated acetyltransferase activity ( TADA2B sgRNAs), or de-ubiquitinase activity ( ENY2 sgRNA). c, Schematic illustrating inhibition of histone-modifying modules of SAGA/ATAC complexes using chemical probes to target SAGA/ATAC-dependent histone acetylation (GSK4027, CPTH2, garcinol), SAGA-dependent H2A/H2B de-ubiquitination (USP22si-02), or <t>WDR5-mediated</t> H3K4me3 methylation (OICR-9529, WM856, <t>WDR5-IN-4,</t> and WDR5-IN-6). d, Average normalized cell viability from CellTiter-Glo assays conducted seven days after starting treatment of H3K27M mutant cells (teal curves) or non-transformed, H3 wildtype, control cells (black curves) with increasing doses of the KAT2A/2B bromodomain-targeting acetyltransferase inhibitor, GSK4027. e, Immunoblots confirming that treatment of BT245 cells with GSK4027 reduced H3K9ac in a dose-dependent manner, but not total H3 or SGF29 protein abundance. f-h, Dose response curves showing inhibition of H3K27M mutant DMG cell viability, but no effect on control H3 wild-type cells (black curves) following seven days of treatment with the DUB inhibitor, USP22i-S02 ( f, yellow curves), the WDR5 WIN site inhibitor, WDR5-IN-4 ( g, blue curves), or the WDR5 WBM site inhibitor, WDR5-IN-6 ( h, blue curves). i-j Average number of live SU-DIPGXIIIP*+ZsG/luc cells ( i ), and average BT245 ( j ) cell viability (CellTiter-Glo) following treatment with combinations of GSK4027 and USP22si-02 to simultaneously target both SAGA/ATAC-dependent histone acetyltransferase activity and SAGA-dependent H2A/H2B de-ubiquitination. k-l, BLISS synergy plots showing a combined effect of GSK4027 and WDR5-IN-6 treatment in reducing SU-DIPGXIIIP*+ZsG/luc growth ( k, **p<1.74×10 -3 ), and a combined effect of GSK4027 and WDR5-IN-4 treatment in reducing BT245 cell growth ( l , ****p<2.5×10 -10 ).
    Hy 111753a, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/wdr5+in+4/WDR5-IN-4/pmc11554307-224-4-3
    Average 94 stars, based on 1 article reviews
    hy 111753a - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    (A–D) Wild-type (WT) T cells were labeled with CFSE and activated in the presence of MM-401, WDR5-IN-4, or DMSO. After 4 days, cells were analyzed by flow cytometry to assess the effects of MM-401 (A) and WDR5-IN-4 (B) on cell division (CFSE dilution), and by RT-PCR to determine the effects of these inhibitors on Sell (C) and Tcf7 (D) transcription. Data are representative of two independent experiments. (E, F) Naïve CD8⁺ T cells were isolated from WT mice and activated in vitro for 4 days to generate activated T cells. Naïve and activated T cells were compared for Tcf7 expression by RT-PCR (E) and for H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (F). Data are representative of two independent experiments. (G, H) Mll1KO and WT T cells were activated in vitro and analyzed after 4 days for Tcf7 transcription by RT-PCR (G) and H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (H). Data are representative of three independent experiments. (I, J) Thymocytes and B cells were isolated from WT mice and compared for Tcf7 transcription by RT-PCR (I) and H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (J). Data are representative of two independent experiments.

    Journal: bioRxiv

    Article Title: The MLL1–MENIN complex preserves CD8 T cell memory through a TOX–BTLA-TCF1 axis

    doi: 10.64898/2026.04.03.715913

    Figure Lengend Snippet: (A–D) Wild-type (WT) T cells were labeled with CFSE and activated in the presence of MM-401, WDR5-IN-4, or DMSO. After 4 days, cells were analyzed by flow cytometry to assess the effects of MM-401 (A) and WDR5-IN-4 (B) on cell division (CFSE dilution), and by RT-PCR to determine the effects of these inhibitors on Sell (C) and Tcf7 (D) transcription. Data are representative of two independent experiments. (E, F) Naïve CD8⁺ T cells were isolated from WT mice and activated in vitro for 4 days to generate activated T cells. Naïve and activated T cells were compared for Tcf7 expression by RT-PCR (E) and for H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (F). Data are representative of two independent experiments. (G, H) Mll1KO and WT T cells were activated in vitro and analyzed after 4 days for Tcf7 transcription by RT-PCR (G) and H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (H). Data are representative of three independent experiments. (I, J) Thymocytes and B cells were isolated from WT mice and compared for Tcf7 transcription by RT-PCR (I) and H3K4me3 enrichment at the Tcf7 locus by ChIP-PCR (J). Data are representative of two independent experiments.

    Article Snippet: Small-molecule inhibitors used included AKT inhibitor MK-2206 (selleckchem) used at 0.05uM, AKT inhibitor AKTi-1/2 (selleckchem) used at 0.5uM, Menin inhibitor MI-3454 used at 0.25uM, Wdr5 inhibitor WDR5-IN-4 (Medchemexpress) used at 2.5uM, Wdr5 inhibitor MM-401 (invivochem) used at 25uM, Thymidine (for S-phase arrest) used at 2mM (sigma-aldrich), Nocodazole (for mitotic arrest) used at 0.5uM (selleckchem).

    Techniques: Labeling, Flow Cytometry, Reverse Transcription Polymerase Chain Reaction, Isolation, In Vitro, Expressing

    (A) Wild-type (WT) T cells were activated in the presence of WDR5-IN-4, MM-401, or DMSO. After 4 days, cells were collected and analyzed for Tox expression by RT-PCR. Data are representative of two independent experiments. (B, E) T cells from Mll1KO mice and their WT littermates were activated in vitro. After 4 days, cells were collected and analyzed for H3K4me3 (B) and H4K16ac (E) enrichment at the Tox locus by ChIP-PCR. Data are representative of three independent experiments. (C, D, F) Thymocytes and B cells were isolated from WT mice and compared for Tox expression by RT-PCR (C), and for H3K4me3 (D) and H4K16ac (F) enrichment at the Tox locus by ChIP-PCR. Data are representative of two independent experiments. (G, H) T cells from Mll1KO mice and their WT littermates were activated in the presence of MI-3454 or DMSO. After 4 days, cells were collected and analyzed for Tox (G) and Btla (H) expression by RT-PCR. Data are representative of two independent experiments.

    Journal: bioRxiv

    Article Title: The MLL1–MENIN complex preserves CD8 T cell memory through a TOX–BTLA-TCF1 axis

    doi: 10.64898/2026.04.03.715913

    Figure Lengend Snippet: (A) Wild-type (WT) T cells were activated in the presence of WDR5-IN-4, MM-401, or DMSO. After 4 days, cells were collected and analyzed for Tox expression by RT-PCR. Data are representative of two independent experiments. (B, E) T cells from Mll1KO mice and their WT littermates were activated in vitro. After 4 days, cells were collected and analyzed for H3K4me3 (B) and H4K16ac (E) enrichment at the Tox locus by ChIP-PCR. Data are representative of three independent experiments. (C, D, F) Thymocytes and B cells were isolated from WT mice and compared for Tox expression by RT-PCR (C), and for H3K4me3 (D) and H4K16ac (F) enrichment at the Tox locus by ChIP-PCR. Data are representative of two independent experiments. (G, H) T cells from Mll1KO mice and their WT littermates were activated in the presence of MI-3454 or DMSO. After 4 days, cells were collected and analyzed for Tox (G) and Btla (H) expression by RT-PCR. Data are representative of two independent experiments.

    Article Snippet: Small-molecule inhibitors used included AKT inhibitor MK-2206 (selleckchem) used at 0.05uM, AKT inhibitor AKTi-1/2 (selleckchem) used at 0.5uM, Menin inhibitor MI-3454 used at 0.25uM, Wdr5 inhibitor WDR5-IN-4 (Medchemexpress) used at 2.5uM, Wdr5 inhibitor MM-401 (invivochem) used at 25uM, Thymidine (for S-phase arrest) used at 2mM (sigma-aldrich), Nocodazole (for mitotic arrest) used at 0.5uM (selleckchem).

    Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, In Vitro, Isolation

    a, Growth curves of SU-DIPGXIII cells transduced with shRNAs to knockdown both KAT2A and KAT2B, showing significantly reduced growth compared to control shRNA-transduced cells. b, Number of live SU-DIPGXIII+Cas9 cells expressing a control plasmid (HA/flag-GFP) or sgRNAs to KO SAGA-associated acetyltransferase activity ( TADA2B sgRNAs), or de-ubiquitinase activity ( ENY2 sgRNA). c, Schematic illustrating inhibition of histone-modifying modules of SAGA/ATAC complexes using chemical probes to target SAGA/ATAC-dependent histone acetylation (GSK4027, CPTH2, garcinol), SAGA-dependent H2A/H2B de-ubiquitination (USP22si-02), or WDR5-mediated H3K4me3 methylation (OICR-9529, WM856, WDR5-IN-4, and WDR5-IN-6). d, Average normalized cell viability from CellTiter-Glo assays conducted seven days after starting treatment of H3K27M mutant cells (teal curves) or non-transformed, H3 wildtype, control cells (black curves) with increasing doses of the KAT2A/2B bromodomain-targeting acetyltransferase inhibitor, GSK4027. e, Immunoblots confirming that treatment of BT245 cells with GSK4027 reduced H3K9ac in a dose-dependent manner, but not total H3 or SGF29 protein abundance. f-h, Dose response curves showing inhibition of H3K27M mutant DMG cell viability, but no effect on control H3 wild-type cells (black curves) following seven days of treatment with the DUB inhibitor, USP22i-S02 ( f, yellow curves), the WDR5 WIN site inhibitor, WDR5-IN-4 ( g, blue curves), or the WDR5 WBM site inhibitor, WDR5-IN-6 ( h, blue curves). i-j Average number of live SU-DIPGXIIIP*+ZsG/luc cells ( i ), and average BT245 ( j ) cell viability (CellTiter-Glo) following treatment with combinations of GSK4027 and USP22si-02 to simultaneously target both SAGA/ATAC-dependent histone acetyltransferase activity and SAGA-dependent H2A/H2B de-ubiquitination. k-l, BLISS synergy plots showing a combined effect of GSK4027 and WDR5-IN-6 treatment in reducing SU-DIPGXIIIP*+ZsG/luc growth ( k, **p<1.74×10 -3 ), and a combined effect of GSK4027 and WDR5-IN-4 treatment in reducing BT245 cell growth ( l , ****p<2.5×10 -10 ).

    Journal: bioRxiv

    Article Title: SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma

    doi: 10.64898/2026.01.22.701194

    Figure Lengend Snippet: a, Growth curves of SU-DIPGXIII cells transduced with shRNAs to knockdown both KAT2A and KAT2B, showing significantly reduced growth compared to control shRNA-transduced cells. b, Number of live SU-DIPGXIII+Cas9 cells expressing a control plasmid (HA/flag-GFP) or sgRNAs to KO SAGA-associated acetyltransferase activity ( TADA2B sgRNAs), or de-ubiquitinase activity ( ENY2 sgRNA). c, Schematic illustrating inhibition of histone-modifying modules of SAGA/ATAC complexes using chemical probes to target SAGA/ATAC-dependent histone acetylation (GSK4027, CPTH2, garcinol), SAGA-dependent H2A/H2B de-ubiquitination (USP22si-02), or WDR5-mediated H3K4me3 methylation (OICR-9529, WM856, WDR5-IN-4, and WDR5-IN-6). d, Average normalized cell viability from CellTiter-Glo assays conducted seven days after starting treatment of H3K27M mutant cells (teal curves) or non-transformed, H3 wildtype, control cells (black curves) with increasing doses of the KAT2A/2B bromodomain-targeting acetyltransferase inhibitor, GSK4027. e, Immunoblots confirming that treatment of BT245 cells with GSK4027 reduced H3K9ac in a dose-dependent manner, but not total H3 or SGF29 protein abundance. f-h, Dose response curves showing inhibition of H3K27M mutant DMG cell viability, but no effect on control H3 wild-type cells (black curves) following seven days of treatment with the DUB inhibitor, USP22i-S02 ( f, yellow curves), the WDR5 WIN site inhibitor, WDR5-IN-4 ( g, blue curves), or the WDR5 WBM site inhibitor, WDR5-IN-6 ( h, blue curves). i-j Average number of live SU-DIPGXIIIP*+ZsG/luc cells ( i ), and average BT245 ( j ) cell viability (CellTiter-Glo) following treatment with combinations of GSK4027 and USP22si-02 to simultaneously target both SAGA/ATAC-dependent histone acetyltransferase activity and SAGA-dependent H2A/H2B de-ubiquitination. k-l, BLISS synergy plots showing a combined effect of GSK4027 and WDR5-IN-6 treatment in reducing SU-DIPGXIIIP*+ZsG/luc growth ( k, **p<1.74×10 -3 ), and a combined effect of GSK4027 and WDR5-IN-4 treatment in reducing BT245 cell growth ( l , ****p<2.5×10 -10 ).

    Article Snippet: The following compounds were used in this study: SGF29-IN-1 (cat# HY-158009, MedChemExpress), GSK4027 (cat# SML2018, Sigma Aldrich), CPTH2 (cat# J65939LB0, ThermoFisher), garcinol (cat# 14076, Active Motif), USP22si-02 (cat# SML3875, Sigma Aldrich), WDR5-IN-4 (WIN site inhibitor, cat# HY-111753, MedChemExpress), WDR5-IN-6 (WBM site inhibitor, cat# T77495, TargetMol), OICR9429 (cat# T6916, TargetMol), WM586 (WDR5/Myc inhibitor, cat# HY-153728, MedChemExpress), YM-53601 (cat# HY-100313A, MedChemExpress), NB-598 (cat# HY-16343, MedChemExpress), terbinafine (cat# T3677, TCI Chemicals), Atorvastatin (cat# SML3030, Sigma Aldrich), and Pitavastatin (cat# AMBH2D6EF677, Ambeed)

    Techniques: Transduction, Knockdown, Control, shRNA, Expressing, Plasmid Preparation, Activity Assay, Inhibition, Ubiquitin Proteomics, Methylation, Mutagenesis, Transformation Assay, Western Blot, Quantitative Proteomics

    a, Growth curves of SU-DIPGXIII cells transduced with shRNAs to knockdown both KAT2A and KAT2B, showing significantly reduced growth compared to control shRNA-transduced cells. b, Number of live SU-DIPGXIII+Cas9 cells expressing a control plasmid (HA/flag-GFP) or sgRNAs to KO SAGA-associated acetyltransferase activity ( TADA2B sgRNAs), or de-ubiquitinase activity ( ENY2 sgRNA). c, Schematic illustrating inhibition of histone-modifying modules of SAGA/ATAC complexes using chemical probes to target SAGA/ATAC-dependent histone acetylation (GSK4027, CPTH2, garcinol), SAGA-dependent H2A/H2B de-ubiquitination (USP22si-02), or WDR5-mediated H3K4me3 methylation (OICR-9529, WM856, WDR5-IN-4, and WDR5-IN-6). d, Average normalized cell viability from CellTiter-Glo assays conducted seven days after starting treatment of H3K27M mutant cells (teal curves) or non-transformed, H3 wildtype, control cells (black curves) with increasing doses of the KAT2A/2B bromodomain-targeting acetyltransferase inhibitor, GSK4027. e, Immunoblots confirming that treatment of BT245 cells with GSK4027 reduced H3K9ac in a dose-dependent manner, but not total H3 or SGF29 protein abundance. f-h, Dose response curves showing inhibition of H3K27M mutant DMG cell viability, but no effect on control H3 wild-type cells (black curves) following seven days of treatment with the DUB inhibitor, USP22i-S02 ( f, yellow curves), the WDR5 WIN site inhibitor, WDR5-IN-4 ( g, blue curves), or the WDR5 WBM site inhibitor, WDR5-IN-6 ( h, blue curves). i-j Average number of live SU-DIPGXIIIP*+ZsG/luc cells ( i ), and average BT245 ( j ) cell viability (CellTiter-Glo) following treatment with combinations of GSK4027 and USP22si-02 to simultaneously target both SAGA/ATAC-dependent histone acetyltransferase activity and SAGA-dependent H2A/H2B de-ubiquitination. k-l, BLISS synergy plots showing a combined effect of GSK4027 and WDR5-IN-6 treatment in reducing SU-DIPGXIIIP*+ZsG/luc growth ( k, **p<1.74×10 -3 ), and a combined effect of GSK4027 and WDR5-IN-4 treatment in reducing BT245 cell growth ( l , ****p<2.5×10 -10 ).

    Journal: bioRxiv

    Article Title: SAGA/ATAC complexes sustain aberrant chromatin regulation and promote tumorigenesis in diffuse midline glioma

    doi: 10.64898/2026.01.22.701194

    Figure Lengend Snippet: a, Growth curves of SU-DIPGXIII cells transduced with shRNAs to knockdown both KAT2A and KAT2B, showing significantly reduced growth compared to control shRNA-transduced cells. b, Number of live SU-DIPGXIII+Cas9 cells expressing a control plasmid (HA/flag-GFP) or sgRNAs to KO SAGA-associated acetyltransferase activity ( TADA2B sgRNAs), or de-ubiquitinase activity ( ENY2 sgRNA). c, Schematic illustrating inhibition of histone-modifying modules of SAGA/ATAC complexes using chemical probes to target SAGA/ATAC-dependent histone acetylation (GSK4027, CPTH2, garcinol), SAGA-dependent H2A/H2B de-ubiquitination (USP22si-02), or WDR5-mediated H3K4me3 methylation (OICR-9529, WM856, WDR5-IN-4, and WDR5-IN-6). d, Average normalized cell viability from CellTiter-Glo assays conducted seven days after starting treatment of H3K27M mutant cells (teal curves) or non-transformed, H3 wildtype, control cells (black curves) with increasing doses of the KAT2A/2B bromodomain-targeting acetyltransferase inhibitor, GSK4027. e, Immunoblots confirming that treatment of BT245 cells with GSK4027 reduced H3K9ac in a dose-dependent manner, but not total H3 or SGF29 protein abundance. f-h, Dose response curves showing inhibition of H3K27M mutant DMG cell viability, but no effect on control H3 wild-type cells (black curves) following seven days of treatment with the DUB inhibitor, USP22i-S02 ( f, yellow curves), the WDR5 WIN site inhibitor, WDR5-IN-4 ( g, blue curves), or the WDR5 WBM site inhibitor, WDR5-IN-6 ( h, blue curves). i-j Average number of live SU-DIPGXIIIP*+ZsG/luc cells ( i ), and average BT245 ( j ) cell viability (CellTiter-Glo) following treatment with combinations of GSK4027 and USP22si-02 to simultaneously target both SAGA/ATAC-dependent histone acetyltransferase activity and SAGA-dependent H2A/H2B de-ubiquitination. k-l, BLISS synergy plots showing a combined effect of GSK4027 and WDR5-IN-6 treatment in reducing SU-DIPGXIIIP*+ZsG/luc growth ( k, **p<1.74×10 -3 ), and a combined effect of GSK4027 and WDR5-IN-4 treatment in reducing BT245 cell growth ( l , ****p<2.5×10 -10 ).

    Article Snippet: The following compounds were used in this study: SGF29-IN-1 (cat# HY-158009, MedChemExpress), GSK4027 (cat# SML2018, Sigma Aldrich), CPTH2 (cat# J65939LB0, ThermoFisher), garcinol (cat# 14076, Active Motif), USP22si-02 (cat# SML3875, Sigma Aldrich), WDR5-IN-4 (WIN site inhibitor, cat# HY-111753, MedChemExpress), WDR5-IN-6 (WBM site inhibitor, cat# T77495, TargetMol), OICR9429 (cat# T6916, TargetMol), WM586 (WDR5/Myc inhibitor, cat# HY-153728, MedChemExpress), YM-53601 (cat# HY-100313A, MedChemExpress), NB-598 (cat# HY-16343, MedChemExpress), terbinafine (cat# T3677, TCI Chemicals), Atorvastatin (cat# SML3030, Sigma Aldrich), and Pitavastatin (cat# AMBH2D6EF677, Ambeed)

    Techniques: Transduction, Knockdown, Control, shRNA, Expressing, Plasmid Preparation, Activity Assay, Inhibition, Ubiquitin Proteomics, Methylation, Mutagenesis, Transformation Assay, Western Blot, Quantitative Proteomics